Companies / BridgeBio Pharma, Inc.

BridgeBio Pharma, Inc.

Nasdaq: BBIOCIK 1743881PALO ALTO, CA

Financials · FY2025

Revenue$502.08M
Net income$-732.94M
Total debt$2.65B
Cash$677.91M
Diluted EPS$-3.78
Shares outstanding195.5M

Ownership

195.5M shares outstanding · as of Aug 3, 2026
3.5%Insiders
Ownership
Insiders3.45%6,752,817
Institutions97.12%189,853,518
Public float0.00%0

Reported holdings exceed shares outstanding — public float shown as 0; some positions may overlap or lag.

% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insiders 12

View all →
Insider% of sharesShares
Kumar NeilCEOChief Executive Officer · Director
2.72%5,308,584
Homcy Charles JDirector
0.47%919,876
Trimarchi ThomasPresident and CFO
0.20%395,626
Apuli MaricelFormerChief Accounting Officer
0.07%136,115
Hassan FredDirector
0.02%29,879
Daniels Ronald JDirector
0.01%20,981
Momtazee James CDirector
<0.01%19,070
Ellis AndreaDirector
<0.01%18,589
Scott Randal W.Director
<0.01%11,589
Aguiar EricDirector
<0.01%10,579

Institutional holders 445

View all →
HolderValue% of shares
Vanguard Group Inc$1.29B8.63%
Kohlberg Kravis Roberts & Co. L.P.$984.76M6.78%
Janus Henderson Group PLC$978.61M6.74%
Viking Global Investors LP$879.42M6.06%
BlackRock, Inc.$766.19M5.26%
Farallon Capital Management LLC$688.29M4.60%
Aisling Capital Management LP$389.30M2.60%
Geode Capital Management, LLC$371.93M2.52%
Invesco Ltd.$369.55M2.47%
State Street Corporation$330.39M2.27%

Activity

View all →
InsidersInstitutions
What insiders are doing in this stock (Form 4).
DateActorActionSecurityValueShares ΔPosition afterImpact
Mar 4, 2026Ellis Andrea
Director
SellCommon Stock$4.21M-65K
-77.74%
18,589
<0.01% of shares
medium
Feb 16, 2026Kumar Neil
CEO
OtherCommon Stock$2.33M-31K
-10.55%
262,504
0.13% of shares
low
Feb 16, 2026Trimarchi Thomas
Executive
OtherCommon Stock$1.42M-19K
-5.10%
350,185
0.18% of shares
low
Feb 19, 2026Kumar Neil
CEO
SellCommon Stock$1.34M-19K
-7.21%
243,581
0.12% of shares
medium
Feb 27, 2026Valantine Hannah
Director
ExerciseCommon Stock$1.23M+25K
+341.38%
32,949
0.02% of shares
low
Feb 10, 2026Kumar Neil
CEO
SellCommon Stock$1.02M-14K
-1.98%
701,485
0.36% of shares
medium
Feb 10, 2026Kumar Neil
CEO
SellCommon Stock$1.01M-14K
-0.31%
4,504,407
2.30% of shares
medium
Feb 17, 2026Trimarchi Thomas
Executive
SellCommon Stock$1.00M-13K
-3.83%
336,785
0.17% of shares
medium

5%+ ownership events

Schedule 13D / 13G
FilerStance% of classSharesDate
Vanguard Group IncPassive13G/A—0—
Janus Henderson Group PLCPassive13G———
Farallon Capital Partners, L.P.Passive13G———
Janus Henderson Group PLCPassive13G/A———

Securities

via CUSIP / OpenFIGI
SymbolTypeMarketCUSIPFIGI
BBIO——10806X102—